LHA 510

Drug Profile

LHA 510

Alternative Names: LHA-510

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon
  • Class Eye disorder therapies
  • Mechanism of Action Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 25 Jul 2017 Phase-II development is ongoing for Wet age-related macular degeneration in USA
  • 01 Oct 2016 Alcon completes a phase II trial in Wet Age-related macular degeneration (In adults, In the elderly) in USA (Ophthalmic) (NCT02355028)
  • 04 Mar 2015 Phase-II clinical trials in Wet Age-related macular degeneration (In adults, In the elderly) in USA (Ophthalmic) (NCT02355028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top